BIMATOPROST | N022184 | ABBVIE INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| E.D.N.Y. | 2025-12-19 | Terminated 2026-01-30 | — | |
Allergan, Inc. et al v. Amneal Pharmaceuticals of New York, LLC et al 1 patentbimatoprost | E.D.N.Y. | 2023-08-17 | Terminated 2025-09-14 | — |
| D. Del. | 2023-03-13 | Terminated 2024-10-29 | — | |
| E.D. Tex. | 2011-08-26 | Terminated 2014-01-13 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Pfizer Inc. - Citizen Petition FDA-2006-P-0072 · 9 docket documents Pfizer Inc. filed this citizen petition under 21 C.F.R. 10.30 requesting that the FDA revoke Allergan Inc.'s supplemental NDA #21-275/5-013 approval for Lumigan (bimatoprost ophthalmic solution 0.03%) for a first-line indication and deny Alcon Inc.'s supplemental NDA #21-257 for Travatan (travoprost | 505(q) | 2008-09-29 | Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$103.21
per ml
Lowest NADAC/Unit
$103.13
per ml
Brand NDCs
3
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00023320503LUMIGAN 0.01% EYE DROPS | $103.21 | ML | Brand | $60.41 | 2026-06-17 |
| 00023320508LUMIGAN 0.01% EYE DROPS | $103.21 | ML | Brand | $65.20 | 2026-06-17 |
| 00023320505LUMIGAN 0.01% EYE DROPS | $103.13 | ML | Brand | $62.23 | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 7851504 | Jun 13, 2027 | — | Yes | Yes | — | — |